Form 4 for VRCA Verrica Pharmaceuticals Inc.
Accepted 2025-11-25 00:00:00 ET · period of report 2025-11-25 · accession 0001556327-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-11-25 | 2025-11-25 | VRCA | Kirby John J. | Interim CFO | P - Purchase | $4.24 | +3,536 | 8,962 | +65% | +$15.0K |
| D | 2025-11-25 | 2025-11-25 | VRCA | Kirby John J. | Interim CFO | P - Purchase | — | +884 | 884 | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-25 | P | A | 3,536 | $4.24 | 8,962 | D | — | — | (F1) Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. |
| 2 | Derivative | Series C Warrant (right to buy) | 2025-11-25 | P | A | 884 | — | 884 | D | $6.32 · — to 2030-11-25 | 884 Common Stock | (F3) The reported securities are included within 3,536 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. (F2) Immediately exercisable. |